Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 9/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | WNT1 | P04628 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | PAICS | P22234 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216260 | 0.81 | CHEK2 (0.35) | TOP2AHSP90AB1CHEK2WNT1GSK3B | |
| Hydrochloric Acid SCHEMBL216946 | 0.80 | TOP2A (0.35) | TOP2AHSP90AB1CHEK2WNT1GSK3B | |
| SCHEMBL214823 | 0.78 | CHEK2 (0.35) | TOP2AHSP90AB1CHEK2WNT1GSK3B | |
| Hydrochloric Acid SCHEMBL213800 | 0.77 | CHEK2 (0.35) | TOP2AHSP90AB1CHEK2WNT1GSK3B | |
| SCHEMBL214470 | 0.77 | KDM1A (0.44) | TOP2AHSP90AB1CHEK2PAICS | |
| Hydrochloric Acid SCHEMBL213798 | 0.76 | KDM1A (0.43) | TOP2AHSP90AB1CHEK2PAICS | |
| SCHEMBL214581 | 0.76 | TOP2A (0.43) | TOP2AHSP90AB1 | |
| SCHEMBL214720 | 0.74 | HCAR1 (0.35) | — | |
| SCHEMBL214143 | 0.73 | KDM1A (0.42) | TOP2AHSP90AB1CHEK2WNT1GSK3B | |
| SCHEMBL214697 | 0.73 | KDM1A (0.42) | CHEK2WNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-2061768-A2 | IMIDAZOLE-4,5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | Exelixis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008042282-A2 | IMIDAZOLE-4, 5-DICARBOXAMIDE DERIVATIVES AS JAK-2 MODULATORS | EXELIXIS, INC. (US) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | TOP2A 1957/4885HSP90AB1 1319/4885CHEK2 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.